Psychotropic Medication GDR and Diagnosis Review Failure
Summary
The facility failed to follow physician orders for gradual dose reduction (GDR) evaluation for psychotropic medications and failed to discontinue a psychotropic medication for a resident whose psychiatric diagnosis was recommended for removal from the medical record. This deficiency affected 2 residents in a sample of 64. The report states that the facility did not complete the required GDR process as described in its own policy and did not ensure psychotropic use was supported by an appropriate diagnosis and documented reduction attempts. One resident had diagnoses including nontraumatic intracerebral hemorrhage, hemiplegia and hemiparesis following cerebral infarction, epilepsy, convulsions, hypertension, acute kidney disease, and aphasia. The resident had an active order for quetiapine 50 mg daily related to schizoaffective disorder, and the medication was administered throughout May, June, and July 2025. The resident’s MDS showed no BIMS, and the MDS mood section documented rare symptoms of little interest or pleasure, feeling down, and trouble sleeping. A physician admission/follow-up schizophrenia diagnosis evaluation documented that a comprehensive evaluation validated that schizophrenia should be removed from the medical record because it did not meet DSM-5-TR criteria. The second resident had diagnoses including schizoaffective disorder, bipolar type, major depressive disorder, anxiety disorder, alcohol dependence in remission, hemiplegia and hemiparesis, lack of coordination, limitation of activities due to disability, and insomnia. The resident had active orders for Seroquel 100 mg and Depakote 500 mg, with administration documented in May and June 2025. The resident’s MDS showed a BIMS score of 10 and rare symptoms of depression and sleep difficulty. The Administrator stated residents taking psychotropic medications should have a quarterly GDR, and the Director of Clinical Services stated psychotropic medication should have a diagnosis before use and that GDRs should occur twice in the first year and when clinically indicated. The facility policy required the interdisciplinary team to review psychotropic use for diagnosis support, target behaviors, and documented reduction attempts.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release August 26, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.